Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (331-340 of 399) with videos related to

Pageof 40
Sort By:
International Urology and Nephrology|January 19, 2022
Prognostic value of metabolic syndrome in renal structural changes in type 2 diabetesLijun Zhao, Yutong Zou, Lin Bai, et al.
JAMA|September 2, 2015
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical TrialGeorge L Bakris, Rajiv Agarwal, Juliana C Chan, et al.
Kidney International|May 14, 2010
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathySally A Penfold, Melinda T Coughlan, Sheila K Patel, et al.
Frontiers in Physiology|June 26, 2020
Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney DiseaseAnna M D Watson, Eleanor A M Gould, Sarah C Moody, et al.
Diabetes Research and Clinical Practice|June 9, 2012
Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetesSusan van Dieren, Andre P Kengne, John Chalmers, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 22, 2026
Mitochondrial Alterations and CKDJairo A Pinzon-Cortes, Phoom Narongkiatikhun, Long Yuan, et al.
Journal of Medicinal Chemistry|June 17, 2021
Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A<sub>4</sub> Mimetics (QNX-sLXms)Monica de Gaetano, Catherine Tighe, Kevin Gahan, et al.
Diabetes Research and Clinical Practice|September 25, 2023
Circulating epigenomic biomarkers correspond with kidney disease susceptibility in high-risk populations with type 2 diabetes mellitusIshant Khurana, Natasha J Howard, Scott Maxwell, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Zhongxin Zhang, Paulette A Lyle, et al.
Diabetes Care|March 24, 2016
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ONMuh Geot Wong, Vlado Perkovic, John Chalmers, et al.
Pageof 40

Showing results (331-340 of 399) with videos related to

Sort By:
Pageof 40
International Urology and Nephrology|January 19, 2022
Prognostic value of metabolic syndrome in renal structural changes in type 2 diabetesLijun Zhao, Yutong Zou, Lin Bai, et al.
JAMA|September 2, 2015
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical TrialGeorge L Bakris, Rajiv Agarwal, Juliana C Chan, et al.
Kidney International|May 14, 2010
Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathySally A Penfold, Melinda T Coughlan, Sheila K Patel, et al.
Frontiers in Physiology|June 26, 2020
Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney DiseaseAnna M D Watson, Eleanor A M Gould, Sarah C Moody, et al.
Diabetes Research and Clinical Practice|June 9, 2012
Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetesSusan van Dieren, Andre P Kengne, John Chalmers, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 22, 2026
Mitochondrial Alterations and CKDJairo A Pinzon-Cortes, Phoom Narongkiatikhun, Long Yuan, et al.
Journal of Medicinal Chemistry|June 17, 2021
Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A<sub>4</sub> Mimetics (QNX-sLXms)Monica de Gaetano, Catherine Tighe, Kevin Gahan, et al.
Diabetes Research and Clinical Practice|September 25, 2023
Circulating epigenomic biomarkers correspond with kidney disease susceptibility in high-risk populations with type 2 diabetes mellitusIshant Khurana, Natasha J Howard, Scott Maxwell, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Zhongxin Zhang, Paulette A Lyle, et al.
Diabetes Care|March 24, 2016
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ONMuh Geot Wong, Vlado Perkovic, John Chalmers, et al.
Pageof 40